-
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes.
DiabetesGreenbaum CJ, Schatz DA, Haller MJ, Sanda S -
Perspective: Rethink the immune connection.
NatureGreenbaum CJ -
Dead or alive?
Diabetes CareGreenbaum CJ -
Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant.
J ImmunolHabib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum CJ, Rawlings DJ, Buckner JH -
Effect of rituximab on human in vivo antibody immune responses.
J Allergy Clin ImmunolPescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum CJ, Herold KC, Skyler JS, Weinberg A, Type 1 Diabetes TrialNet Study Group. -
Making progress: preserving beta cells in type 1 diabetes.
Ann N Y Acad SciGallagher MP, Goland RS, Greenbaum CJ -
Metabolic tests to determine risk for type 1 diabetes in clinical trials.
Diabetes Metab Res RevGreenbaum CJ, Buckingham B, Chase HP, Krischer J, Diabetes Prevention Trial, Type 1 Diabetes (DPT-1) Study Group. -
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study.
Diabetes CareSosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. -
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
LancetOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
LancetWherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group. -
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363.
DiabetesSanda S, Greenbaum CJ -
Parenteral insulin suppresses T cell proliferation to islet antigens.
Pediatr DiabetesGreenbaum CJ, McCulloch-Olson M, Chiu HK, Palmer JP, Brooks-Worrell B -
Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database.
Diabetes CareTridgell DM, Spiekerman C, Wang RS, Greenbaum CJ -
A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.
Pediatr DiabetesSosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, Diabetes Prevention Trial-Type 1 and TrialNet Study Groups. -
Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes.
DiabetesGreenbaum CJ, Atkinson MA
